Nasdaq
$3.99▲ 0.25%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $37.3MShares out 9.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 1d agoAfter-hours26.10.24 06:48SCHEDULE 13GOwnership#●●●
Adicet Bio, Inc.
Daniel Clayton Zedek and Lauren Marie Zedek have filed a Schedule 13G to report their joint beneficial ownership of Adicet Bio, Inc. common stock. The filers hold these shares through joint brokerage accounts or individual retirement accounts and constitute a group for reporting purposes.…more
$3.99+0.25%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.28Pre-market26.09.28 21:158-KKey event
Adicet Bio, Inc.
Adicet Bio announced positive Phase 1 clinical data for Prula-cel (formerly ADI-001) in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN). At the 12-month mark, 50% of evaluable LN patients achieved complete renal response (CRR) and 54% of evaluable patients achieved DORIS remission, with all patients discontinuing immunosuppressants. The company plans to initiate start-up activities for a pivotal study in LN in the fourth quarter of 2026.…more
$3.99+0.25%vs prev closeView filingShare - 9.8After-hours26.09.09 05:178-KKey event
Adicet Bio, Inc.
Adicet Bio released an investor presentation on September 8, 2026, detailing the clinical development status and future milestones for its lead candidates, prula-cel and ADI-212. Prula-cel is being developed as an off-the-shelf CAR-T therapy for autoimmune diseases, while the company plans to initiate clinical enrollment for ADI-212 in metastatic castration-resistant prostate cancer (mCRPC) in Q4 2026.…more
$3.99+0.25%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.28Pre-market26.09.28 19:49Bullish#●●●#●●●#●●●
Adicet Bio Reports Positive Phase 1 Data for Lupus Treatment Prula-Cel
Adicet Bio announced positive safety and efficacy results from its Phase 1 study of Prula-Cel in lupus patients, showing high remission rates and good tolerability. The company plans to initiate a pivotal trial for lupus nephritis in the fourth quarter of 2026.…more
$3.99+0.25%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.25After-hours26.09.26 05:01
●●●●●●●● ●●●●● ●●●●●●
Adicet Bio will release Phase 1 clinical data for its lupus treatment candidate, prulacabtagene leucel, on September 28. The company will host a webcast presentation following the announcement to discuss the study results.…more
$3.99+0.25%vs prev closeShareBenzinga - 9.1Pre-market26.09.01 20:03
●●●●●●●● ●●●●● ●●●●●●
Adicet Bio has completed the final patient visit for its 22-patient Phase 1 analysis of its systemic lupus erythematosus treatment. Topline data from the study is expected to be released in September 2026.…more
$3.99+0.25%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report